Keywords: USA, FDA, ESAs, Amgen, Aranesp, Epogen, Johnson & Johnson, Procrit, Erythropoiesis-stimulating agents, Cardiovascular events
US FDA modifies dosing for ESA’s Aranesp, Epogen and Procrit on cardiovascular risks
Article | 27 June 2011
The US Food and Drug Administration on Friday recommended more conservative dosing guidelines for erythropoiesis-stimulating agents (ESAs) when used to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
